Clinical Trial Detail

NCT ID NCT03053440
Title A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors BeiGene
Indications

lymphoplasmacytic lymphoma

Therapies

Ibrutinib

Zanubrutinib

Age Groups: adult senior

No variant requirements are available.